Research SummaryKey Findings

What research findings does B7-33 have in fibrosis regulation?

B7-33 reduces left ventricular fibrosis and improves some cardiovascular tissue indicators. Another study reports: reduces cell death and adverse remodeling, preserves heart function.[1] ↗ [2] ↗

Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
i

Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.

Comparison of study design and results

Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.

LiteratureStudy subjects and designObservation and discoveryScope of Explanation
2023 · PMID 36753958Mouse isoproterenol cardiomyopathy modelB7-33 reduces left ventricular fibrosis and improves some cardiovascular tissue indicators.Preclinical; not equivalent to efficacy in human heart failure.
2020 · PMID 32295457Mouse myocardial infarction and myocardial cellsReduce cell death and adverse remodeling, preserve cardiac function.Animal mechanism studies.
2019 · PMID 31713411Subcutaneous implantation of PLGA-coated materials in miceCoating of B7-33 reduces fibrous capsule thickness.Local implantation coating, different from systemic injection.

References

Animal Study2023REF. 01

What does the study of left ventricular fibrosis in cardiomyopathy models indicate?

Research Findings

B7-33 reduces left ventricular fibrosis and improves some cardiovascular tissue indicators.[1] ↗

Study Design

Mouse isoproterenol cardiomyopathy model

Scope & Limitations

Preclinical; not equivalent to efficacy in human heart failure.

View the Article Title and Full Citation＋

The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy.

Alam F, Gaspari TA, Kemp-Harper BK, Low E, Aw A, Ferens D, Spizzo I, Jefferis AM, Praveen P, Widdop RE, Bathgate RAD, Hossain MA, Samuel CS.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie · Volume/Issue Year 2023
First published 2023-02-06 · PMID 36753958
DOI 10.1016/j.biopha.2023.114370

Published · Original ResearchPubMed ↗Journal Article ↗
Animal / experimental studies2020 · Historical basic researchREF. 02

What changes occur in adverse remodeling in myocardial infarction mice?

Research Findings

Reduce cell death and adverse remodeling, preserve cardiac function.[2] ↗

Study Design

Mouse myocardial infarction and myocardial cells

Scope & Limitations

Animal mechanism studies.

View the Article Title and Full Citation＋

B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice.

Devarakonda T, Mauro AG, Guzman G, Hovsepian S, Cain C, Das A, Praveen P, Hossain MA, Salloum FN.

Journal of the American Heart Association · Volume and Issue Year 2020
First published 2020-04-16 · PMID 32295457
DOI 10.1161/jaha.119.015748

Published · Original ResearchPubMed ↗Journal Article ↗
Animal Study2019 · Historical basic researchREF. 03

How does B7-33 release coating study fibrous capsules?

Research Findings

Coating of B7-33 reduces fibrous capsule thickness.[3] ↗

Study Design

Subcutaneous implantation of PLGA-coated materials in mice

Scope & Limitations

Local implantation coating, different from systemic injection.

View the Article Title and Full Citation＋

Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation.

Welch NG, Mukherjee S, Hossain MA, Praveen P, Werkmeister JA, Wade JD, Bathgate RAD, Winkler DA, Thissen H.

ACS Applied Materials & Interfaces · Volume/Issue Year 2019
First published 2019-12-02 · PMID 31713411
DOI 10.1021/acsami.9b17859

Published · Original ResearchPubMed ↗Journal Article ↗

Common issues and corresponding evidence

What research findings does B7-33 have in fibrosis regulation?＋

B7-33 reduces left ventricular fibrosis and improves some cardiovascular tissue indicators. Another study reports: reduces cell death and adverse remodeling, preserves heart function.[1] ↗ [2] ↗

Can anti-fibrosis research on B7-33 be directly applied to humans?＋

Currently Not Possible. This involves animal myocardial remodeling and implant coating release; local materials and systemic intervention conditions differ and cannot be considered proof for human treatment.[1] ↗ [2] ↗ [3] ↗

B7-33—these conclusions apply to which study populations?＋

Mouse isoproterenol cardiomyopathy model; mouse myocardial infarction and myocardial cells; subcutaneous implantation of PLGA-coated materials in mice. Preclinical; not equivalent to human heart failure efficacy.[1] ↗ [2] ↗ [3] ↗

B7-33

Return to catalog specifications and batch file verification entry.

↗